| Proteomics, Metabolomics & Biomarkers (3)

Learn more about our ligand binding assays and how they can support biological drug testing in a regulated environment, including:

Regulated bioanalysis
Immunogenicity
Immunotoxicity
Biomarkers (safety and efficacy)
Clinical Pathology
Sample Management
Additional activities

DOWNLOAD

This article forms a book chapter in Artificial Intelligence in Drug Design.

In this review article, we discuss the use of machine learning approaches in large omics studies

The chapter includes:

an overview of the typical analysis of an omics dataset using machine learning
demonstration of how to build a model predicting drug-induced liver injury (DILI) using transcriptomics data
best practices and pitfalls to consider during initial data exploration and model training through to validation and analysis of the final model

LEARN MORE

Fireside Chat at BIO-Europe 2021

Evotec Chief Scientific Officer, Dr Cord Dohrmann, talks to Dr Hubert Birner, Managing Partner at TVM Capital Life Sciences, about how Evotec has built an impressive and innovative platform.

WATCH NOW

Mass spectrometry (MS)-based ubiquitinomics allows a system-level understanding of ubiquitin signalling.

In this publication, we focus on:

a background to ubiquitinome profiling
presentation of a scalable and robust workflow for deep and precise in vivo ubiquitinome profiling using DIA-MS (data-independent acquisition mass spectrometry) and neural network based data processing
comprehensive mapping of substrates of deubiquitinase USP7, an anticancer drug target known to regulate tumour suppressor p53
application of the method including rapid mode of action profiling of candidate drugs targeting deubiquitinases or ubiquitin ligases

LEARN MORE

Science Pool

Ligand Binding Assays Fact Sheet

Machine Learning using Omics Data

How to Build an Innovative Pipeline- Dr. Cord Dohrmann, Evotec

Fireside Chat at BIO-Europe 2021

Time-Resolved Ubiquitinome Profiling by DIA-MS Reveals USP7 Targets

Fast and Straightforward Biomarker Identification in PanHunter

AhR as a Molecular Target of the Utrophin Modulator Ezutromid

A Multidisciplinary Approach to Gene Therapy Development

Can Biomarkers help us to Develop Personalised Medicine Faster?

How Proteomics Boosts the Discovery of Novel Drugs and Biomarkers

Phosphorylation Signatures Predict Response to Dasatinib